Find a Doctor

Christopher J. Hoimes

University Hospitals Medical Group Inc
Oncology, Hospitalist, Internal Medicine
Male
Practicing approx. 20 years

Bio


Christopher Hoimes is an Oncologist and an Internal Medicine specialist in Chapel Hill, North Carolina. He has been an author on 45 peer reviewed articles in the past 15 years. He is licensed to treat patients in CT and OH.

Contact

300 Meadowmont Village Cir
Suite 311
Chapel Hill, NC 27517, US

Latest Research


Latest Advance
Study
  • Condition: Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Gemcitabine-Eribulin
  • Number of Patients: 24
  • Published —
This trial assessed the tolerability and effectiveness of a gemcitabine-eribulin combination in patients with metastatic urothelial carcinoma ineligible for cisplatin-based treatments.
Latest Advance
Study
  • Condition: CD70-positive, metastatic renal cell carcinoma
  • Journal: Cancer
  • Treatment Used: SGN-CD70A
  • Number of Patients: 18
  • Published —
The purpose of the study was to evaluate the safety and tolerability of SGN-CD70A for the treatment of CD70-positive, metastatic renal cell carcinoma.
Latest Advance
Study
  • Condition: Patients with Previously Treated Metastatic Adrenocortical Carcinoma (mACC)
  • Journal: Journal for immunotherapy of cancer
  • Treatment Used: Avelumab
  • Number of Patients: 50
  • Published —
This study assessed the effectiveness and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC).
Latest Advance
Study
  • Condition: Patients with Castration-Resistant and Neuroendocrine Prostate Cancer (NEPC)
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Aurora Kinase A Inhibitor Alisertib
  • Number of Patients: 60
  • Published —
This study evaluated men with metastatic neuroendocrine prostate cancer (NEPC) treated with alisertib 50 mg twice daily for 7 days every 21 days.

Clinical Trials


This doctor has not participated in any recent clinical trials.

All Publications
View All


Publication
Conference
  • Sponsor: Society for ImmunoTherapy of Cancer (SITC)
  • Event Name: Society for ImmunoTherapy of Cancer Annual Scientific Meeting 2020
  • Published —
CLINICAL OUTCOMES OF OVARIAN CANCER PATIENTS TREATED WITH ALKS 4230, A NOVEL ENGINEERED CYTOKINE, IN COMBINATION WITH PEMBROLIZUMAB: ARTISTRY-1 TRIAL

Contact

300 Meadowmont Village Cir
Suite 311
Chapel Hill, NC 27517, US

Affiliations

  • University Hospitals Of Cleveland
  • Duke University Hospital
  • University Hospitals Ahuja Medical Center

Credentials

  • Graduate InstitutionNew York College Of Osteo Medicine Of New York Institute Of Technology
    2001
  • Licenses
    Internal Medicine in CT
  • Board Certifications
    Medical Oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.